A First in Human Single Ascending Dose (SAD) Study of ATI-1013 in Healthy Smokers

Clinical trial NCT07215923 · RECRUITING

Trial details

NCT number: NCT07215923
Sponsor: Antidote Therapeutics, Inc
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Thromboangiitis Obliterans (Buerger's Disease)

Start date: 2025-10-01
Primary completion: 2026-06-30
Enrollment: 15

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.